RxDoctor Payments Data

Sarah Lee, MD

Hematology · Duarte, CANPI 1255741328

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,770 of the $6,690 with a category attached, or 71.3%. 11 manufacturers reported payments, led by Johnson & Johnson at 59.1% of the total. Reporting peaked in 2023 at $3,733 and has fallen 57.1% since, to $1,602 in 2025. That places this record below the midpoint for hematology clinicians in CA, where the typical reported total is $4,615.

$6,690in general payments, 2019–2025

Across 28 payments — averaging $238.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$4K
  • Janssen Scientific Affairs, LLC$2K
  • Alnylam Pharmaceuticals Inc.$150
  • Bristol Myers Squibb$150
  • Regeneron$110
  • Legend Biotech USA Inc.$105
  • plus $333 from 5 others
$1,944,750in research payments, 2019–2025

Across 96 payments — averaging $20,258 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Beigene, Ltd.$1M
  • Janssen Research & Development, LLC$496K
  • GSK$358K
  • Regeneron$69K

What the payments were for

  • Consulting fees$4,77071%
  • Food & beverage$1,62624%
  • Education$2944%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,690 in reported general payments places this provider in the 50th percentile of 178 hematology providers in California.

See all hematology providers in California

Medicare billing

Part B allowed, 2024
$53,006
Medicare patients
101
Services billed
496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide29$481,469
EliquisApixaban15$8,115
Dexamethasone13$305
Acyclovir22$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$150$481,46929 claims
PfizerEliquis$78$8,11515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 178 hematology providers in California.

Other hematology in Duarte

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →